EDC4

Across TCGA pan-cancer cohorts, EDC4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EDC4 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher EDC4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EDC4 expression acts as an unfavorable survival marker.

BRCA, ESCA, and LIHC are the cancer types where EDC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	III,IV	0.019	0.881	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.140	0.525	.011	12	view →
LIHC	DFS	Median	II,III,IV	0.041	0.430	<.001	6	view →
COAD	DFS	Median	II,III,IV	0.131	0.551	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EDC4–BRCA (DFS)

Open the BRCA breakdown →